Court Decision Means Longer Wait For Clarity On EMA’s Access To Documents Policy
Executive Summary
The EU court’s dismissal of appeals filed by the European Medicines Agency in cases relating to its access to documents policy means stakeholders will have to wait even longer to get legal clarity on the policy. One lawyer believes that the case could result in a broader definition of what constitutes commercially confidential information.
You may also be interested in...
Pharma Opposes 'Harmful' Changes To EMA’s Access To Documents Policy
The EU pharmaceutical industry has concerns about the European Medicines Agency’s proposal to grant extended access to documents on orphan designations and pediatric investigation plans under its revised access to documents policy. The changes would discourage innovation and lead to inadvertent disclosure of commercially sensitive data, companies claim.
It’s Started: EMA Proactively Publishes Clinical Data On New Drugs
The European Medicines Agency has delivered on its promise to grant public access to clinical reports that form the basis of its recommendations to the European Commission on whether or not a medicine should be authorized for use in the EU.
EMA Appeals Interim EU Court Orders Preventing Access To Documents
The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.